Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Ticker
$PCVX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
414
ISIN
US92243G1085
Website
Vaxcyte Metrics
BasicAdvanced
$4.2B
-
-$3.98
1.20
-
Price and volume
Market cap
$4.2B
Beta
1.2
52-week high
$116.95
52-week low
$27.66
Average daily volume
1.9M
Financial strength
Current ratio
17.697
Quick ratio
17.235
Long term debt to equity
2.534
Total debt to equity
2.725
Profitability
EBITDA (TTM)
-626.907
Management effectiveness
Return on assets (TTM)
-14.53%
Return on equity (TTM)
-19.66%
Valuation
Price to book
1.31
Price to tangible book (TTM)
1.31
Price to free cash flow (TTM)
-7.025
Free cash flow yield (TTM)
-14.23%
Free cash flow per share (TTM)
-463.77%
Growth
Earnings per share change (TTM)
-5.64%
3-year earnings per share growth (CAGR)
21.78%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Bulls say / Bears say
Vaxcyte's VAX-31 vaccine demonstrated robust immune responses in adults over 50, meeting or exceeding immunogenicity criteria for all 31 serotypes at mid and high doses, positioning it as a strong competitor in the pneumococcal vaccine market. (nasdaq.com)
Analysts project that VAX-31 could capture over 50% of the projected $10 billion pneumococcal conjugate vaccine market by 2030, indicating significant revenue potential. (markets.businessinsider.com)
Vaxcyte maintains a strong financial position with a cash balance of $1.24 billion as of December 31, 2023, providing ample resources to advance its vaccine candidates through clinical development. (stocktitan.net)
Vaxcyte's stock plummeted 56% in a month following mixed results from a Phase II study of VAX-24 in infants, where the vaccine failed to meet non-inferiority criteria for four of the 24 serotypes compared to Pfizer's Prevnar 20. (nasdaq.com)
The broader biotech sector faces uncertainty due to the resignation of a senior FDA official, potentially impacting regulatory clarity and innovation momentum, which could affect Vaxcyte's future approvals. (nasdaq.com)
Despite a strong cash position, Vaxcyte reported a net loss of $402.3 million for the full year 2023, reflecting high R&D expenses and raising concerns about the company's path to profitability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Vaxcyte News
AllArticlesVideos
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
GlobeNewsWire·2 months ago
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $4.2B as of June 30, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of June 30, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.